Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690456 · ClinicalTrials.gov registry record · Phase 3
Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
NCT00690456 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 403 participants.
The verdict
NCT00690456, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes. Secondary objectives include evaluation of other markers of glycemic control, lipid profile, body weight, and abdominal obesity. Also, the trial will study the safety of rimonabant when added to metformin over a period of 47 weeks.
Interventions
- DRUG Metformin
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00690456
The ClinicalTrials.gov registry entry for NCT00690456 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00690456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00690456 about?
NCT00690456 is a clinical study titled "Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes". The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes. Secondary objectives include evaluation of other markers of glycemic control, lipid pro...
What is the current status of trial NCT00690456?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2008-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00690456?
The interventions under investigation include: Metformin (DRUG), Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00690456?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.